Pushing boundaries in cardiometabolic-driven disease

GalaxiaBio is building a potentially best-in-class portfolio of targeted therapeutics to transform the treatment of rare metabolic and endocrine disorders, including hyperphagia in Prader-Willi syndrome as a lead indication.

These disorders affect thousands of patients worldwide, characterized by severe metabolic imbalances. Targeting pathways such as ghrelin and leptin offers hope that truly disease-modifying options may be on the horizon for patients.

Our programs are designed to redefine the standard-of-care for these diseases.

View our corporate deck